RXTECHNOLOGIES – Trademark Portfolio
Entity Type: 03
RXTECHNOLOGIES holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SYRSPEND. The owner is based in ROSEMOUNT, MN.
12510 DANBURY WAY
ROSEMOUNT, MN 55068
Showing of trademarks Trademarks
Trademark Classifications
RXTECHNOLOGIES's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Machines and machine tools; motors and engines; machine coupling and transmission components
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does RXTECHNOLOGIES have?
RXTECHNOLOGIES has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.
What trademark classes does RXTECHNOLOGIES file in?
RXTECHNOLOGIES files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 7 (Machinery), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are RXTECHNOLOGIES's most well-known trademarks?
RXTECHNOLOGIES's registered trademark portfolio includes well-known marks such as SYRSPEND. These are among 1 currently registered trademark in the portfolio.
What is RXTECHNOLOGIES's trademark registration success rate?
RXTECHNOLOGIES has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.